Abstract
Background: Facial lesions including lupus pernio are often a form of chronic cutaneous sarcoidosis.
Objective: To evaluate the intra- and inter-observer consistency of objective measures of chronic facial lesions.
Method: This was a retrospective study of patients with chronic cutaneous facial lesions including lupus pernio. The lesions were evaluated using two methods.
Results: Of the 25 patients studied, 23 were women and 24 were African American. Lungs (24 patients), sinuses (11 patients), and eyes (7 patients) were also affected. The Sarcoidosis Activity and Severity Index (SASI) characterized individual areas of the face, with 95% of the observations being less than 2 points from the median. A facial SASI total gave a score for the entire face and 93.2% of the scores were within 3 points of the median.
Conclusion: Patients with sarcoidosis and chronic facial lesions often have lung, sinus, and eye involvement. The SASI is a reproducible scoring system for chronic facial lesions.
Similar content being viewed by others
References
James DG. Lupus pernio. Lupus 1992 May; 1 (3): 129–31
Spiteri MA, Matthey F, Gordon T. Lupus pernio: a clinico-radiological study of thirty-five cases. Br J Dermatol 1985 Mar; 112 (3): 315–22
Khatri KA, Chotzen VA, Burrall BA. Lupus pernio: successful treatment with a potent topical corticosteroid. Arch Dermatol 1995 May; 131 (5): 617–8
Chloroquine in the treatment of sarcoidosis: a report from the Research Committee of the British Tuberculosis Association. Tubercle 1967 Dec; 48 (4): 257–72
Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand 1964 425: 302S–8S
Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995 155: 846–51
Webster GF, Razsi LK, Sanchez M. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991 24: 451–4
Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004 21: 43–8
Baughman RP, Judson MA, Teirstein AS. Thalidomide for chronic sarcoidosis. Chest 2002 122: 227–32
Carlesimo M, Giustini S, Rossi A. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995 32 (5Pt2): 866–9
Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998 Nov; 39 (5Pt2): 835–8
Nguyen YT, Dupuy A, Cordoliani F. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004 Feb; 50 (2): 235–41
Oliver SJ, Kikuchi T, Krueger JG. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002 Mar; 102 (3): 225–36
Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001 18: 70–4
Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005 Mar; 127 (3): 1064–71
Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 2004 Jan; 150 (1): 146–9
Roberts SD, Wilkes DS, Burgett RA. Refractory sarcoidosis responding to infliximab. Chest 2003 Nov; 124 (5): 2028–31
Hunninghake GW, Costabel U, Ando M. ATS/ERS/WASOG statement on sarcoidosis: American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999 Sep; 16 (2): 149–73
Judson MA, Baughman RP, Teirstein AS. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999 16: 75–86
Altaye M, Donner A, Eliasziw M. A general goodness-of-fit approach for inference procedures concerning the kappa statistic. Stat Med 2001 Aug 30; 20 (16): 2479–88
Neville E, Mills RG, Jash DK. Sarcoidosis of the upper respiratory tract and its association with lupus pernio. Thorax 1976 Dec; 31 (6): 660–4
Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990 Sep; 23 (3Pt1): 487–9
Zic J, Horowitz D, Arzubiaga C. Treatment of cutaneous sarcoidosis with chloroquine: review of the literature. Arch Dermatol 1991 127: 1034–40
Bachelez H, Senet P, Cadranel J. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001 Jan; 137 (1): 69–73
Mallbris L, Ljungberg A, Hedblad MA. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 2003 Feb; 48 (2): 290–3
Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005 Mar; 64Suppl
Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005 210 (3): 194–9
Feldman SR, Fleischer Jr AB, Reboussin DM. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996 Jan; 106 (1): 183–6
Marchell RM, Judson MA. Chronic cutaneous lesions of sarcoidosis. Clin Dermatol 2007 May; 25 (3): 295–302
Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 2004 Oct; 51 (4): 563–9
Antoni CE, Kavanaugh A, Kirkham B. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005 Apr; 52 (4): 1227–36
Carlin CS, Feldman SR, Krueger JG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004 Jun; 50 (6): 859–66
Gordon KB, Papp KA, Hamilton TK. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003 Dec 17; 290 (23): 3073–80
Fernandez C, Adamson K, Dale M. A randomized double-blind study to assess the effects of silicic acid compared to placebo in patients with mild to moderate acne. J Dermatolog Treat 2005 16 (5-6): 287–94
Acknowledgments
Funding for this study was provided by Centocor Inc. The study was used to help establish an instrument for a subsequent trial of infliximab for sarcoidosis (manufactured by Centocor Inc.) that included all the authors of this study. No pharmaceutical agent was tested in the current study. Drs Baughman, Teirstein, and Judson have received grants for research purposes from Centocor Inc. Dr Judson has also received consultancy fees from Centocor Inc. Dr Schlenker-Herceg was an employee of Centocor Inc. at the time of the study. Dr Barnathan is currently an employee of Centocor Inc. The other authors have no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baughman, R.P., Judson, M.A., Teirstein, A. et al. Chronic Facial Sarcoidosis Including Lupus Pernio. Am J Clin Dermatol 9, 155–161 (2008). https://doi.org/10.2165/00128071-200809030-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200809030-00003